Abstract
Lead-compound optimization is an iterative process in the cancer drug development pipeline, in which small molecule inhibitors or biological compounds that are selected for their ability to bind specific targets are synthesised, tested and optimised. This process can be accelerated significantly using molecular imaging with nuclear medicine techniques, which aim to monitor the biodistribution and pharmacokinetics of radiolabelled versions of compounds. Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) can be used to quantify fourdimensional (temporal and spatial) clinically relevant information, to demonstrate tumor uptake of, and monitor the response to treatment with lead-compounds. This review discusses the pre-clinical and clinical value of the information provided by nuclear medicine imaging compared to the histological analysis of biopsied tissue samples. Also, the role of nuclear medicine imaging is discussed with regard to the assessment of the treatment response, radiotracer biodistribution, tumor accumulation, toxicity, and pharmacokinetic parameters, with mention of microdosing studies, pre-targeting strategies, and pharmacokinetic modelling.
Keywords: Biodistribution, cancer, drug delivery, kinetic imaging, microdosing, PET, pretargeting, SPECT.
Current Drug Targets
Title:PET and SPECT Imaging for the Acceleration of Anti-Cancer Drug Development
Volume: 16 Issue: 6
Author(s): Christopher R.T. Hillyar, James C. Knight, Katherine A. Vallis and Bart Cornelissen
Affiliation:
Keywords: Biodistribution, cancer, drug delivery, kinetic imaging, microdosing, PET, pretargeting, SPECT.
Abstract: Lead-compound optimization is an iterative process in the cancer drug development pipeline, in which small molecule inhibitors or biological compounds that are selected for their ability to bind specific targets are synthesised, tested and optimised. This process can be accelerated significantly using molecular imaging with nuclear medicine techniques, which aim to monitor the biodistribution and pharmacokinetics of radiolabelled versions of compounds. Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) can be used to quantify fourdimensional (temporal and spatial) clinically relevant information, to demonstrate tumor uptake of, and monitor the response to treatment with lead-compounds. This review discusses the pre-clinical and clinical value of the information provided by nuclear medicine imaging compared to the histological analysis of biopsied tissue samples. Also, the role of nuclear medicine imaging is discussed with regard to the assessment of the treatment response, radiotracer biodistribution, tumor accumulation, toxicity, and pharmacokinetic parameters, with mention of microdosing studies, pre-targeting strategies, and pharmacokinetic modelling.
Export Options
About this article
Cite this article as:
Hillyar R.T. Christopher, Knight C. James, Vallis A. Katherine and Cornelissen Bart, PET and SPECT Imaging for the Acceleration of Anti-Cancer Drug Development, Current Drug Targets 2015; 16 (6) . https://dx.doi.org/10.2174/1389450116666150330113747
DOI https://dx.doi.org/10.2174/1389450116666150330113747 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches
Current Medicinal Chemistry Molecular and Biochemical Pathways Encompassing Diabetes Mellitus and Dementia
CNS & Neurological Disorders - Drug Targets NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design Treat to Target for Osteoporosis: Another Step Forward
Current Rheumatology Reviews Regional Distribution and Kinetics of Inhaled Pharmaceuticals
Current Pharmaceutical Design Optimizing Tumor-Reactive γδT Cells for Antibody-Based Cancer Immunotherapy
Current Molecular Medicine Overview of the Metallometabolomic Methodology for Metal-Based Drug Metabolism
Current Drug Metabolism Inhibition of Epithelial-mesenchymal Transition in Response to Treatment with Metformin and Y27632 in Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells
Current Cancer Drug Targets Natural Products Targeting Cancer Stem Cells: A Revisit
Current Medicinal Chemistry An Insight of Molecular Mechanisms and Patents of Biomarkers of Human Papilloma Virus Associated with Cancer : A Review
Recent Patents on Biomarkers Molecular Mechanisms and Therapeutic Application of NSAIDs and Derived Compounds in Alzheimers Disease
Current Alzheimer Research Retinoids as Differentiating Agents in Oncology: A Network of Interactions with Intracellular Pathways as the Basis for Rational Therapeutic Combinations
Current Pharmaceutical Design Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence
Current Pharmaceutical Design Clinical Utility of Combined 18F-Fluoro-2-deoxyglucose Positron Emission Tomography – Computed Tomography in the Evaluation of Gastrointestinal Malignancies
Current Medical Imaging Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules
Current Medicinal Chemistry CYP Epoxygenase Derived EETs: From Cardiovascular Protection to Human Cancer Therapy
Current Topics in Medicinal Chemistry DYRK1A Kinase Inhibitors with Emphasis on Cancer
Mini-Reviews in Medicinal Chemistry Current Clinical Applications of Botulinum Toxin
Current Pharmaceutical Design Expression and Function of Kruppel Like-Factors (KLF) in Carcinogenesis
Current Genomics